![136935-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136935-Thumbnail%20Image.png?versionId=aUTdk4C1pX6WU6pL2oGcmKifq.utONV9&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T062707Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=0582479c49cee588a92cd33827975848ece07cd8be233277cdc2019ef70ae3ae&itok=peuQNl6h)
The synergistic effects between Vorinostat and Tamoxifen observed through a phase II study on breast cancer patients resistant to hormone therapy may involve more than the modulation of ER-alpha to reverse Tamoxifen resistance in ERBC cells. RT-qPCR of genes expressed in Tamoxifen resistant cells, trefoil factor 1(TFF1) and v-myc avian myelocytomatosis viral oncogene homolog (MYC), were evaluated along with ESR1 and Diablo as a control. MYC was observed to have increased expression in the treated cells, whereas the other genes had a decrease in their expression levels after the cells were treated for 3 days with Vorinostat IC30 of 1 µM. As for targeting the AR, MCF7 Tamoxifen sensitive and resistant cells were not affected by the AR antagonists to determine an IC50. The cell viability for all MCF7 sub-clones only decreased for high concentrations of 5.56 µM - 50 µM in Bicalutamide and 16.67 µM – 50 µM of MDV1300. Furthermore, hormone depletion of MCF7 G11 Tamoxifen resistant sub-clones did not show a great response to DHT stimulation or the AR antagonists. In the RT-qPCR, the MCF7 G11 cells showed an increase in mRNA expression for ER, AR, and PR after 4 hours of treatment with estradiol. As for the DHT treatment, ER, AR, PR, and PSA had a minimal increase in the fold change, but the fold change in AR was less than in the estradiol treatment. The Mayo Clinic will investigate the possible usage of AR as a biomarker through immunohistochemistry.
![137083-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137083-Thumbnail%20Image.png?versionId=wfwp1XiFhndM_l_D6BlxiGxJKd_iCqnH&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T081554Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=7f1c0534365656ec070d32e6350caa77d0b178b9ed443b5a3019f0da3b259dcb&itok=QEGPPz4v)
![137735-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137735-Thumbnail%20Image.png?versionId=p0eXeP2d03kcFVsH6Euhiot_ftbbE3Gt&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T171244Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=59292f0c61db9dd0f6fad453682f193d9c2d7b6018f4a2523a3f13fdd50cecc3&itok=v4vqSaHP)
![137273-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137273-Thumbnail%20Image.png?versionId=Hu0K4Z1UUNTw5dQPNolgpjvNAy5jiqLb&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240606/us-west-2/s3/aws4_request&X-Amz-Date=20240606T101147Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=cda817c6ebc99ba1eabf93a5773e0c75d207e873997ad0f63b544588498d75ea&itok=E-z8Q_a2)
![137471-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137471-Thumbnail%20Image.png?versionId=oBm7GR8SlMoe01GHGkxRpxffqdtTIygj&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T171244Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=4559ab9e0e7893b04a4275e191362932a202d2e816494fdfe5d803f01d33e3d3&itok=8MaqFm5-)
![136377-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136377-Thumbnail%20Image.png?versionId=p_Ti0vGqEnMl.tQkInTZqTNJfLf.Afrq&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T083032Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=0fbe5f89c06bd1e345eb84c8f00a3cd6c9dbcc088e7e8a648e6fa1a0c8702abb&itok=PPEMWcLm)
![136226-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136226-Thumbnail%20Image.png?versionId=Ly1llGVLDgHpNUj7yi9Web_R.Z7RKOsU&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240605/us-west-2/s3/aws4_request&X-Amz-Date=20240605T091254Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=b6234ef2d5b7926afd08b5a607845150a3f9f338c5914232073cc419a498bd31&itok=g3mlIzwP)
![136571-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136571-Thumbnail%20Image.png?versionId=B_bmZ0K8fCXnwNcGlw_rvi7KyKtlyAbo&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T202724Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5b3949d006bbdf5cf2c62b585b2759b527a29cd9e7b35db738f59734997844c5&itok=t-KZLV2M)
![141461-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-06/141461-Thumbnail%20Image.png?versionId=XX3tbFNKrPAxem2ubZXGWnxpb8BEujXZ&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240602/us-west-2/s3/aws4_request&X-Amz-Date=20240602T100830Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=17cfe72ea48448b83167e21b850f2da436defc089ec8aaf37a2409ed6f84e0ae&itok=GCq4Oc_J)
![148480-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-07/148480-Thumbnail%20Image.png?versionId=corxe.zw..Pmo8fSOFEczA33jK4o.0hm&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T205234Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=bc7690a005762dce9441342bb79953dbb437484b34d7d68a86dcaa9a51200b8d&itok=HPfH7wK2)
Members of the Delphinidae family are widely distributed across the world’s oceans. We used a viral metagenomic approach to identify viruses in orca (Orcinus orca) and short-finned pilot whale (Globicephala macrorhynchus) muscle, kidney, and liver samples from deceased animals. From orca tissue samples (muscle, kidney, and liver), we identified a novel polyomavirus (Polyomaviridae), three cressdnaviruses, and two genomoviruses (Genomoviridae). In the short-finned pilot whale we were able to identify one genomovirus in a kidney sample. The presence of unclassified cressdnavirus within two samples (muscle and kidney) of the same animal supports the possibility these viruses might be widespread within the animal. The orca polyomavirus identified here is the first of its species and is not closely related to the only other dolphin polyomavirus previously discovered. The identification and verification of these viruses expands the current knowledge of viruses that are associated with the Delphinidae family.